Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Prostatic Neoplasms 23Neoplasms 12Lymphoma 4Unspecified Adult Solid Tumor, Protocol Specific 3Neuroblastoma 3Solid Tumors 2Recurrence 2Neoplasm Metastasis 2Lymphoma, Non-Hodgkin 2Glioma 2Glioblastoma 2Brain Neoplasms 2Thromboembolism 1Ovarian Neoplasms 1Oligodendroglioma 1Melanoma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Hematologic Diseases 1Granulosa Cell Tumor 1Genetic Diseases, Inborn 1Castration-resistant Prostate Cancer 1Carcinoma 1Breast Neoplasms 1Astrocytoma 1Advanced Cancer 1

Interventions

pembrolizumab 300Nivolumab 273Ipilimumab 250aldesleukin 137Cyclophosphamide 136Interleukin-2 105trametinib 82dabrafenib 76Temozolomide 75Dacarbazine 74Vemurafenib 71fludarabine 68fludarabine phosphate 62Biopsy 49binimetinib 47sargramostim 44Radiosurgery 44Bevacizumab 43Paclitaxel 42encorafenib 40incomplete Freund's adjuvant 39atezolizumab 38Radiotherapy 37Specimen Handling 36Cisplatin 36CTLA-4 Antigen 36Magnetic Resonance Spectroscopy 35Carboplatin 35cobimetinib 34Introns 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Ketoconazole × Clear all
NCT01765556 2016-11-02

A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma

Hoffmann-La Roche

Phase 1 Withdrawn
Dermatologic

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡